Genome-wide methylation analysis of treatment resistant schizophrenia

[1]  Chao-yong Xiao,et al.  Distinguishing Between Treatment-Resistant and Non-Treatment-Resistant Schizophrenia Using Regional Homogeneity , 2018, Front. Psychiatry.

[2]  T M Hyde,et al.  GAD1 alternative transcripts and DNA methylation in human prefrontal cortex and hippocampus in brain development, schizophrenia , 2018, Molecular Psychiatry.

[3]  P. Menezes,et al.  S14. DNA METHYLATION CHANGES IN GABAERGIC AND GLUTAMATERGIC MARKERS IN EARLY SCHIZOPHRENIA , 2018, Schizophrenia bulletin.

[4]  Frank Dudbridge,et al.  Estimation of a significance threshold for epigenome‐wide association studies , 2017, Genetic epidemiology.

[5]  H. H. Hulshoff Pol,et al.  GABAergic Mechanisms in Schizophrenia: Linking Postmortem and In Vivo Studies , 2017, Front. Psychiatry.

[6]  F. Gaughran,et al.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics , 2016, Pharmacogenomics and personalized medicine.

[7]  Daniel R Weinberger,et al.  Association of DNA Methylation Differences With Schizophrenia in an Epigenome-Wide Association Study. , 2016, JAMA psychiatry.

[8]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[9]  D. Atkinson,et al.  Schizophrenia: overview and treatment options. , 2014, P & T : a peer-reviewed journal for formulary management.

[10]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[11]  A. Mackinnon,et al.  Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis , 2014, Psychological Medicine.

[12]  Matthew E. Ritchie,et al.  illuminaio: An open source IDAT parsing tool for Illumina microarrays , 2013, F1000Research.

[13]  J. Tost,et al.  Complete pipeline for Infinium(®) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. , 2012, Epigenomics.

[14]  K. Gunderson,et al.  High density DNA methylation array with single CpG site resolution. , 2011, Genomics.

[15]  L. Schmidt,et al.  The impact of substance use disorders on the course of schizophrenia—A 15-year follow-up study Dual diagnosis over 15 years , 2011, Schizophrenia Research.

[16]  T. Tollefsbol,et al.  Combined chromatin immunoprecipitation and bisulfite methylation sequencing analysis. , 2011, Methods in molecular biology.

[17]  J. Goldstein,et al.  Sex differences in schizophrenia , 2010, International review of psychiatry.

[18]  S. Faraone,et al.  Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: A preliminary report , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[19]  Julie Kreyenbuhl,et al.  Practice guideline for the treatment of patients with schizophrenia , 1997 .

[20]  L. Niskanen,et al.  Metabolic syndrome in patients with schizophrenia. , 2003, The Journal of clinical psychiatry.

[21]  D Castle,et al.  Psychotic Disorders in Urban Areas: An Overview of the Study on Low Prevalence Disorders , 2000, The Australian and New Zealand journal of psychiatry.

[22]  S. Cole,et al.  Is the earlier age at onset of schizophrenia in males a confounded finding? , 1996, Schizophrenia Research.